SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Benny Leonard

PatientBenny Leonard
Date of birth1976-04-07
IdentifiersMRN HR-BX008-SYN; SSN (made up) 000-08-4106
Document date2026-10-27
AuthorMiriam Okafor-Rosenthal, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Twenty-four-week review: blood pressure, work, mood, worry and aspirin. [S]

History of Present Illness

Mr. Leonard returns six months after intake. He has refereed full cards each week and taught his classes without breathlessness, chest tightness, palpitations or lightheadedness. His home readings over the past week averaged 120/76 mmHg. He takes losartan, amlodipine and atorvastatin every day; the ankle puffiness is slight. He feels less worried about money and sleeps better. He asked again about aspirin, which the cardiologist had raised. [S]

ElementDetail
Home blood pressureAverage 120/76 mmHg over seven days
Mood and worryPHQ-9 2; GAD-7 3
WorkFull cards weekly without symptoms

Review of Systems

SystemResultFinding
CardiovascularNegativeNo chest discomfort, palpitations, fainting or breathlessness at work
GastrointestinalNegativeNo indigestion, black stools or bleeding
PsychiatricNegativeMood good; less worry; sleeping six to seven hours

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Losartan 50 mg with hydrochlorothiazide 12.5 mg, one tablet each morningOne tablet each morningOral route2026-05-12 to 2026-06-30completedS
Losartan 100 mg with hydrochlorothiazide 25 mg, one tablet each morningOne tablet each morning; held from the sick visit; stopped at the preventive visitOral route2026-06-30 to 2026-07-28stoppedS
Atorvastatin 40 mg tablet, one each eveningOne tablet each eveningOral route2026-05-26activeS
Losartan 100 mg tablet, one each morningOne tablet each morning; hold on sick daysOral route2026-07-28activeS
Amlodipine 5 mg tablet, one each morningOne tablet each morningOral route2026-07-28activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-27Body height165cmS
2026-10-27Body weight73kgS
2026-10-27Body mass index (BMI) [Ratio]26.8kg/m2S
2026-10-27Systolic blood pressure122mm[Hg]S
2026-10-27Diastolic blood pressure76mm[Hg]S
2026-10-27Heart rate66/minS
2026-10-27Respiratory rate14/minS
2026-10-27Body temperature36.5CelS
2026-10-27Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S
2026-10-27Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]3{score}S

Physical Exam

Vital signs recorded on 2026-10-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 122/76 mmHg, pulse 66; weight 73.0 kg
CardiovascularRegular rhythm; no murmur; trace ankle edema

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness and tightness across the chest on exertion for about two months, late in long nights of refereeing in hot arenas, easing within a few minutes of rest; never at rest; no fainting, palpitations, orthopnea or ankle swelling; cause under evaluation with a cardiology consultationresolvedconfirmed R06.09S — Synthetic presenting problem anchored to his documented work as a referee; superseded at the consultation when stress testing showed no ischemia and the symptom was attributed to hypertensive heart disease.
Stage 2 hypertension found at a yearly fitness examination for his referee's license (164/100 and 160/98 mmHg), with left ventricular hypertrophy by voltage on the ECG; untreated; home readings to followresolvedconfirmed I10S — Synthetic diagnosis at intake; reclassified as hypertensive heart disease after the echocardiogram at the consultation.
Hypertensive heart disease without heart failure: concentric left ventricular hypertrophy (septum 13 mm, mass index 118 g/m2) with normal ejection fraction, grade 1 diastolic dysfunction, a mildly enlarged left atrium and an exaggerated blood pressure rise on exercise; no features of hypertrophic cardiomyopathyactiveconfirmed I11.9S — Synthetic diagnosis made at the cardiology consultation; not a claim about his real heart.
Coronary atherosclerosis found by coronary calcium scoring (Agatston score 186, about the 80th percentile for his age and sex), without angina and with no inducible ischemia on exercise stress echocardiographyactiveconfirmed I25.10S — Synthetic diagnosis made at the cardiology consultation; not a retrospective diagnosis of the cause of his death, which is disputed.
Hypercholesterolemia: LDL 160 mg/dL, HDL 44 mg/dL, lipoprotein(a) not raised; no diabetesactiveconfirmed E78.00S — Synthetic diagnosis at intake.
Volume depletion after refereeing a long card in a heat wave while taking losartan 100 mg with hydrochlorothiazide 25 mg: lightheaded on standing, with an orthostatic fall in blood pressure, a prerenal rise in creatinine to 1.44 mg/dL and potassium 3.3 mmol/L; no fainting, chest pain or arrhythmiaresolvedconfirmed E86.0S — Synthetic acute problem from the thiazide in summer heat; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationClinic blood pressure, average of two seated readingsEvery visitCompleted today122/76 mmHg
Self-managementHome blood pressure monitoring (validated upper-arm cuff), readings sent weeklyEvery day during titration; then a week before each visitCompleted todaySeven-day average 120/76 mmHg
LaboratoryBasic metabolic panel (sodium, potassium, creatinine, eGFR)Two to four weeks after starting or changing an ARB or diuretic; then every six monthsUp to dateNormal two months ago; next in about four months
LaboratoryUrine albumin-to-creatinine ratioAt diagnosis, then yearlyUp to dateDue a year after intake
LaboratoryHbA1cAt diagnosis, then yearlyUp to dateDue a year after intake
LaboratoryLipid panelFour to twelve weeks after starting a statin; then yearlyUp to dateLDL 66 mg/dL; next a year after starting atorvastatin
ImagingEchocardiogramAt diagnosis of stage 2 hypertension or suspected hypertrophy; repeat in six to twelve months to judge regressionDueRepeat in about six months, a year after the first
ImagingStress testing or coronary imagingFor new or changed exertional symptoms; not for routine surveillanceNot indicatedNo symptoms; routine surveillance testing is not recommended
ExaminationSymptoms: exertional chest discomfort, breathlessness, palpitations, faintingEvery visitCompleted todayNone
ExaminationWeight, BMI and physical activityEvery visitCompleted today73.0 kg, BMI 26.8; brisk walks most mornings
Medication safetyAdherence and side effects (cough, edema, muscle aches, lightheadedness)Every visitCompleted todayNo missed doses; trace ankle edema only
Medication safetyAspirin decisionWhen risk changesCompleted todayShared decision: not started, by his choice; revisit yearly
Self-managementReturn to work: refereeing, heat and hydration, warning symptoms, defibrillator at the venueBefore return to full exertion; then every visitCompleted todayFull cards weekly without symptoms
SurveyDepression screen (PHQ-9)At intake, then yearly or with changeCompleted today2, from 5; item 9 scored 0
SurveyAnxiety screen (GAD-7)At intake, then yearly or with changeCompleted today3, from 6
Self-managementFinancial strain and medicine costEvery visitCompleted todayThree generic medicines at low cost; money steadier

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Recombinant zoster vaccine, dose 2 of 2; Influenza vaccine, inactivated trivalent, this season's formulation [S]

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026); 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (2019); Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (2015); CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and ischemic heart disease monographs (2026); Depression and Suicide Risk in Adults: Screening (2023); Anxiety Disorders in Adults: Screening (2023); Adult Immunization Schedule by Age (2026)

Follow-up: Second hepatitis B and zoster doses and the influenza vaccine today; COVID-19 vaccine at the pharmacy. Basic metabolic panel and urine albumin in about four months. Echocardiogram and lipid panel in about six months. Next preventive visit in July. [S]